Validation of WHO HIV/AIDS Clinical Staging in Uganda
Author Information
Author(s): Baveewo Steven, Ssali Francis, Karamagi Charles, Kalyango Joan N., Hahn Judith A., Ekoru Kenneth, Mugyenyi Peter, Katabira Elly
Primary Institution: Clinical epidemiology unit, College of Health Sciences, Makerere University Kampala, Uganda
Hypothesis
Can WHO HIV/AIDS clinical staging effectively predict low CD4 cell counts in Uganda?
Conclusion
The WHO HIV/AIDS clinical staging guidelines have low sensitivity, indicating that many patients may miss out on timely ART initiation.
Supporting Evidence
- The sensitivity of WHO clinical staging at CD4<250 cells/mm3 was found to be 53.5%.
- Angular cheilitis and papular pruritic eruptions were significant predictors of low CD4 counts.
- About half of the participants in stages 1 and 2 would be eligible for ART initiation if CD4 counts were tested.
Takeaway
This study looked at how well a set of guidelines helps doctors decide when to start HIV treatment. It found that the guidelines often miss patients who need help.
Methodology
A multi-centre, cross-sectional study was conducted with structured questionnaires and laboratory analysis to assess CD4 counts and clinical staging.
Potential Biases
Potential bias due to the convenience sampling method and the blinding of clinicians to CD4 results.
Limitations
The study had a limited sample size to detect associations with rare clinical conditions.
Participant Demographics
Participants had a mean age of 36.8 years, with 68% being female and 92% having primary education.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI for sensitivity and specificity values provided in the results.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website